In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea

Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. doi: 10.1128/AAC.01562-06. Epub 2007 Apr 9.

Abstract

The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.

Publication types

  • Comparative Study

MeSH terms

  • Acetamides / pharmacology
  • Anti-Infective Agents / pharmacology
  • Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / antagonists & inhibitors*
  • Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / chemistry
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • In Vitro Techniques
  • Korea / epidemiology
  • Linezolid
  • Microbial Sensitivity Tests
  • Molecular Structure
  • Oxazolidinones / pharmacology
  • Pyridines / adverse effects
  • Pyridines / pharmacology
  • Staphylococcus / drug effects*
  • Staphylococcus / enzymology
  • Staphylococcus / genetics
  • Staphylococcus / growth & development
  • Staphylococcus / isolation & purification*
  • Staphylococcus aureus / drug effects*
  • Thienopyridines
  • Thiophenes / adverse effects
  • Thiophenes / pharmacology

Substances

  • Acetamides
  • Anti-Infective Agents
  • CG 400549
  • Enzyme Inhibitors
  • Oxazolidinones
  • Pyridines
  • Thienopyridines
  • Thiophenes
  • Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)
  • Linezolid